Key result
Novel pharmacological treatments for heart failure are currently in development, requiring better understanding of drug dosing, integration of therapies, and reliable surrogate markers for success.
This review highlights the ongoing development of novel pharmacological therapies for heart failure and the need for better integration, dosing understanding, and surrogate markers.
Hypothesis-generating for novel HF agents; leaves open dosing, integration, and surrogate validation in prospective trials.
Pharmacological therapies remain the primary strategy for treating patients with acute and chronic heart failure. Several novel neurohormonal antagonists, inotropic agents, immune modulators, and metabolic and replacement therapies are currently in development to meet the demands of an increasing number of patients with heart failure. The success in drug development in this field will require a better understanding of the effects of heart failure on drug dosing, better integration of novel and existing drug therapies, the development of more reliable surrogate markers to effectively tailor medical therapy to individual needs and the ability to detect and treat patients at risk before the onset of heart failure.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2003) conducted a review in heart failure. Novel pharmacological treatments was evaluated. Novel pharmacological treatments for heart failure are currently in development, requiring better understanding of drug dosing, integration of therapies, and reliable surrogate markers for success.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: